Gastrointestinal Stromal Tumor With Primary Resistance to Imatinib and Extensive Bone Metastases

• DOI: 10.1097/mjt.0b013e3181d41eef
• Publication Date: 2010-06-09T10:59:48Z
• Authors: Zeeshan Tariq; Abhimanyu Ghose; Ehsan Rafiq; Iman Mohamed
• Keywords: PDGFRA; Imatinib Mesylate; Stromal tumor

Gastrointestinal stromal tumors (GISTs) are the most common nonepithelial of gastrointestinal tract characterized by mutations activating c-KIT or platelet-derived growth factor receptor alpha. GISTs frequently metastasize to liver and peritoneum, but rarely bones. Imatinib, a tyrosine kinase inhibitor, has revolutionized treatment advanced metastasized both slowing down disease progression prolonging survival. Occasionally, patients with can develop primary secondary resistance imatinib monotherapy. We presenting an interesting case metastatic extensive bone lesions imatinib. Efforts identify metastases using appropriate imaging modalities highly recommended in diagnosed GISTs. Also, alternate strategies overcome emerging single agent chemotherapy warranted.